There are studies reporting that non-selective β-blockers (propranolol, atenolol) may have adverse metabolic effects: blunting the perception of hypoglycemia in patients receiving insulin treatment (especially in type 1 diabetes mellitus, but not exclusively) [217,218], increasing plasma triglycerides [218], amplifying insulin resistance [218,219]. The gene discussed is INS; the disease is Insulin resistance.